Status:
COMPLETED
Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for CO...
Eligibility Criteria
Inclusion
- Age 18-75 years old; both sex;
- ECoG 0 or 1;
- Patients that would undergo biopsy or surgical operation with high ACE2 expression tumors such as colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain cancer or suspected tumor.
- use 18F-FDG PET/CT as baseline evaluation
Exclusion
- Significant hepatic or renal dysfunction;
- Is Pregnant or ready to pregnant;
- Cannot lie on their back for half an hour;
- Suffering from claustrophobia or other mental diseases;
- Refusal to join the clinical study;
Key Trial Info
Start Date :
June 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04422457
Start Date
June 13 2020
End Date
March 1 2022
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ethics Committee of Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142